Figure 1. Progression-free survival in NSCLC patients, with or without immune-related adverse events, based on (1) all patients (n = 44), (2) patients treated with pembrolizumab as the primary therapy (n = 22), and (3) patients treated with pembrolizumab as secondary or more therapy (n = 22). Ticks indicate patients whose data were censored on April 30, 2018. irAE, immune related adverse event; NR, not reached.
Figure 2. Progression-free survival in NSCLC patients with or without skin reactions. Ticks indicate patients whose data were censored on April 30, 2018. NR, not reached.
